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 INTRODUCTION
The Position Statement of the Work Group of the 
Portuguese Society of Nephrology on the treatment 
of chronic kidney disease -related mineral and bone 
disorders (CKD -MBD) published in this issue of the 
Portuguese Journal of Nephrology and Hypertension 
was the result of a thorough literature review accord-
ing to explicit a priori criteria.
Much to our chagrin, the absence of solid evi-
dence in this area has made the Statement quite 
meagre and, if anything, unable to provide clear 
guidance on most topics.
The Expert Panel felt that while waiting for further 
scientific evidence it might be useful to provide 
opinion -based guidance for clinical care, explaining 
how the Expert Panel approaches these questions and 
formulates treatment decisions in their daily practice.
It was felt that in the face of the extremely high 
cardiovascular risk of the CKD population it is not 
wise to wait for the best evidence from clinical tri-
als to treat our patients. Our treatment decisions 
must be based on the best available evidence and 
this includes clinical trials, experimental studies, 
epidemiological data, expert opinion and our own 
experience.
 BIOCHEMICAL TREATMENT TARGETS
  Risks associated with abnormal serum phospho-
rus: target values for treatment
In dialysis patients, observational studies show 
an independent and consistent association between 
increasing serum phosphorus levels and adverse 
clinical outcomes. However, the range at which 
phosphorus is associated with adverse clinical out-
comes varies from study to study, ranging from 
5.0 -5.5 mg/dl to >7.0 mg/dl1 -5.
However, the Expert Panel acknowledged that 
there are no randomised trials evaluating the effect 
of lowering serum phosphorus to a specific threshold 
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on patients’ clinical outcomes. Therefore, the benefits 
of lowering phosphorus levels on patients’ clinical 
outcomes (e.g. mortality, cardiovascular events, 
hospitalisation, and bone fracture) are currently 
unknown.
The Expert Panel believes that treatment should 
target thresholds beyond which there is most likely 
an increased risk for patient health. Therefore, clini-
cians should avoid phosphorus values that were 
associated with an increased risk of adverse out-
comes in observational studies.
Recently published observational data showed 
that the risk of cardiovascular mortality was signifi-
cantly greater for phosphorus levels greater than 6.0 
mg/dl, with the greatest risk of mortality for phos-
phorus levels of 7.0 mg/dl or greater5.
  Risks associated with abnormal serum calcium: 
target values for treatment
In CKD stage 5D patients, observational studies 
show an independent and consistent association 
between increasing serum calcium levels and adverse 
clinical outcomes. However, the range at which cal-
cium is associated with adverse clinical outcomes 
varies from study to study, ranging from >9.5 mg/dl 
to >11.4 mg/dl1,3 -5. At the low end of serum calcium 
levels the evidence of an increased risk of adverse 
clinical outcomes is less consistent.
Additionally, the Expert Panel acknowledged that 
there are no randomised trials evaluating the effect 
of lowering serum calcium to a specific threshold (or 
avoiding high calcium levels, meaning above a spe-
cific threshold) on patients’ clinical outcomes. There-
fore, the benefits of lowering calcium levels (or 
avoiding high calcium levels) on patients’ clinical 
outcomes are currently unknown.
The Expert Panel believes that in their phar-
macologic intervention clinicians should avoid 
high calcium levels, meaning calcium levels that 
were associated with an increased risk of adverse 
outcomes in observational studies. Survival mod-
els based on observational data published 
recently identified categories with the greatest 
risk of mortality for calcium levels greater than 
10.0 mg/dl5.
  Risks associated with abnormal serum parathyroid 
hormone (PTH): target values for treatment
In dialysis patients, observational studies show-
ing an association between increasing PTH values 
and adverse clinical outcomes have been inconsis-
tent. In all these studies, PTH analyses have been 
complicated by problems with assay methods and 
poor precision. Additionally, the range at which PTH 
is associated with adverse clinical outcomes varies 
from study to study, ranging from >400 pg/ml to 
>600 pg/ml1,3 -5.
Additionally, the Expert Panel acknowledged that 
there are no randomised trials evaluating the effect 
of lowering serum PTH to a specific threshold on 
patients’ clinical outcomes. Therefore, the benefits 
of lowering PTH levels on patients’ clinical outcomes 
are currently unknown.
The Expert Panel believes that treatment should 
target thresholds beyond which there is most likely 
an increased risk for patient health. Therefore, the 
Expert Panel believes that clinicians should avoid 
PTH values that were associated with an increased 
risk of adverse outcomes in observational studies. 
Survival models based on observational data pub-
lished recently identified categories with the greatest 
risk of mortality for PTH levels greater than 600 pg/
dl5. Additionally, the Expert Panel believes clinicians 
should take into account preceding values and long-
term trends in PTH values.
In conclusion, the Expert Panel believes clinicians 
should lower phosphate and PTH levels, avoiding 
values that were associated with an increased risk 
of adverse outcomes in observational studies. Fur-
thermore, in their pharmacologic intervention, the 
Expert Panel believes clinicians should avoid high 
calcium levels, meaning calcium levels that were 
associated with an increased risk of adverse out-
comes in observational studies
  SURROGATE ENDPOINTS: ARE THEY 
USEFUL FOR TREATMENT?
A surrogate endpoint is an endpoint that is 
intended to stand in for a clinical outcome in the 
evaluation of therapeutic efficacy in clinical trials. 
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Surrogate endpoints are statistically related with 
morbid events and are useful markers of the under-
lying disease. Amelioration of the surrogate marker 
as a result of an intervention is expected to be 
associated with an improvement in the underlying 
disease. However, in CKD patients, it has not yet 
been demonstrated that the effect of treatment on 
surrogate endpoints (biochemical endpoints – calcium, 
phosphorus and PTH, and intermediate endpoints 
– bone biopsy data or vascular calcification progres-
sion) will reduce the occurrence of patients’ clinical 
endpoints (mortality, cardiovascular events, hospi-
talisations, fractures, quality of life), making them 
non -validated surrogate markers for patients’ clinical 
outcomes.
It is important to remember that absence of evi-
dence does not have the same meaning as evidence 
of absence. However, clinicians should be aware that 
although reliance on non -validated surrogate end 
points may, in some cases, be beneficial, there are 
several examples in the past in which it has been 
shown to be harmful.
  Vascular Calcifications: a useful surrogate endpoint?
The association of vascular calcifications with 
lower survival is verified in predialysis and dialysis 
patients, and is considered to be a consistent asso-
ciation based on epidemiological studies.
In several clinical trials6 -8, the progression of 
vascular calcifications seems to be modified by the 
choice of phosphate binder; it is reduced in patients 
treated with sevelamer hydrochloride while progres-
sion is verified in the majority of patients treated 
with calcium -based phosphate binders. However, 
these are not consistent findings, as they were not 
observed in other studies9,10. Additionally, there are 
no studies evaluating whether altering the progres-
sion of calcification will impact on important patient 
outcomes.
Currently, there is no diagnostic method validated 
to stratify cardiovascular risk in CKD patients based 
on vascular calcification (plain X -ray, echocardiogra-
phy, ultrasound or coronary Agatston score evalu-
ated by computed tomography), and therefore sys-
tematic screening of vascular calcifications is not 
recommended. However, it is considered that knowl-
edge of the presence of vascular calcifications may 
be used to individualise treatment in CKD patients. 
At this stage of knowledge, we can only interfere in 
a very small number of factors, mainly alterations in 
mineral metabolism.
  EFFECT OF PHOSPHATE BINDERS 
ON BONE HISTOLOGY
Studies of the effect of phosphate binders on 
bone histology have been performed comparing 
sevelamer hydrochloride and lanthanum carbonate 
with calcium -based phosphate binders. Lanthanum 
carbonate11,12 and sevelamer hydrochloride13 do not 
cause adverse effects on bone. Sevelamer increases 
bone formation rate and ameliorates trabecular micro 
architecture. The clinical importance of these findings 
is currently unknown.
  NOVEL EFFECTS OF VITAMIN D 
THERAPY?
Even though there is a lack of RCT data showing 
an improvement in patient clinical outcomes (all 
cause mortality, cardiovascular mortality, morbidity, 
hospitalisations, fractures), in CKD stages 3 -5D 
patients treated with vitamin D, the Expert Panel 
considers the following aspects relevant for thera-
peutic decisions:
CKD patients frequently present not only 1,25(OH)2-
-D3 insufficiency/deficiency, but also 25(OH) -D3 
insufficiency/deficiency14 -17.
Vitamin D is known to have pleiotropic extra-
skeletal effects, including modulation of immune 
function, inflammatory responses, cell cycle regula-
tion, insulin resistance and, in animal models, vas-
cular smooth muscle cell hypertrophy and angio-
tensin system regulation18 -21.
In addition to the kidney, emerging data shows 
that 1 -alpha hydroxylation occurs in many extra renal 
tissues such as cardiomyocytes, immune cells, and 
vascular smooth muscle cells22,23.
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25(OH) -D3 deficiency may play a direct role in 
many of the disturbances associated with lack of 
vitamin D24. 25(OH) -D3 deficiency / insufficiency has 
been associated with increased vascular calcification 
and arterial stiffness25.
More than 130,000 patients were included in 
several observational retrospective and prospec-
tive studies, in which a reduction in all cause 
mortality and / or cardiovascular mortality was 
associated with the use of calcitriol or new vita-
min D analogue therapy versus non -vitamin D 
therapy3,26 -28. Although these findings were not 
present in all studies, they are relevant to point 
out testable hypothesis that need to be confirmed 
with RCT.
A distinction between “physiological” doses of 
vitamin D (to correct insufficiency / deficiency of 
vitamin D) and “pharmacological” doses of vitamin 
D, to control SHPT (secondary hyperparathyroidism), 
should be considered28.
There are no studies comparing safety and effi-
cacy of the different new vitamin D analogues.
The Expert Panel suggests:
Serum 25(OH) -D3 insufficiency/deficiency can be 
corrected with oral colecalciferol. A dose of 100 IU 
/day will increase, approximately, serum 25(OH) -D3 
in 1 ng/ml29,30.
As vitamin D intoxication has not been found for 
serum 25(OH)D3 levels <200 ng/ml and a daily intake 
below 10000 IU, a wide “safe therapy window,” is 
observed30.
Calcitriol and vitamin D analogues are effective in 
controlling SHPT, but the increase in serum calcium 
and serum phosphate frequently limits their use in 
high pharmacological doses. The association of 
vitamin D or vitamin D analogues with calcimimetics 
may be useful in the treatment of secondary hyper-
parathyroidism.
Based on the paucity of RCT, the Expert Panel 
cannot recommend the preferential use of calcitriol 
or a specific vitamin D analogue for treatment of 
SHPT.
 SHOULD WE USE CALCIMIMETICS?
In observational studies, SHPT in chronic kidney 
disease stage 5D is associated with increased risk 
of bone fractures1,31 -33, proximal miopathy34, unex-
plained bone pain34 and mortality1,35. Also there is 
an association between hyperphosphataemia and 
hypercalcaemia with morbidity and mortality1. How-
ever, there are no RCT demonstrating a beneficial 
effect of controlling SHPT with calcimimetic agents 
on clinical outcomes such as fracture, bone pain, 
cardiovascular morbidity and mortality.
Treatment with the calcimimetic agent, cinacalcet, 
has been shown in RCT to be efficacious in suppress-
ing parathyroid hormone secretion, with a simultane-
ous decrease in calcium and phosphorus levels36 -38.
A prospective, double -blind, placebo -controlled 
trial assessed the effects of cinacalcet on bone histol-
ogy and serum markers of bone metabolism in dialy-
sis patients with SHPT39. Treatment with cinacalcet 
lowered PTH, improved bone histology, and reduced 
bone turnover and tissue fibrosis among most dialy-
sis patients with SHPT. However, the clinical impor-
tance of these findings is currently unknown.
The Expert Panel acknowledged that the risk of 
developing adynamic bone disease with cinacalcet 
treatment is low when used only in patients with 
evidence of high bone turnover and avoiding PTH 
oversuppression39.
The Expert Panel believes that, in CKD stage 5D 
patients with SHPT, calcimimetic agents are highly 
specific therapeutic agents that effectively lower 
concentrations of plasma PTH and partially correct 
disturbances in mineral metabolism. However, there 
is a need for randomised controlled trials evaluating 
the impact of treating SHPT with calcimimetics on 
patient clinical outcomes such as fracture rate, car-
diovascular morbidity and mortality. The EVOLVE 
trial is ongoing and this issue is to be reassessed 
after its publication.
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